Status:
COMPLETED
Placebo and Active Controlled Study of Rivoglitazone in Type 2 Diabetes
Lead Sponsor:
Daiichi Sankyo
Conditions:
Type 2 Diabetes
Eligibility:
All Genders
18-75 years
Phase:
PHASE2
PHASE3
Brief Summary
This is a 6-month study to evaluate the effects of monotherapy with rivoglitazone, an insulin sensitizer, on glycemic control in newly identified type 2 diabetics or diabetics not adequately treated w...
Eligibility Criteria
Inclusion
- Type 2 diabetes in male or female patients
- Between 18 and 75 years of age
- With a HbA1c greater than or equal to 7.5% and less than 10.5% at randomization
Exclusion
- Type 1 diabetics or type 2 diabetics currently on insulin therapy
- Patients unwilling or unable to discontinue their anti-diabetic medication(s)
- History of ketoacidosis
- History of therapy with rosiglitazone, troglitazone, pioglitazone
Key Trial Info
Start Date :
December 1 2004
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2005
Estimated Enrollment :
441 Patients enrolled
Trial Details
Trial ID
NCT00143520
Start Date
December 1 2004
End Date
December 1 2005
Last Update
May 10 2021
Active Locations (74)
Enter a location and click search to find clinical trials sorted by distance.
1
Birmingham, Alabama, United States
2
Columbiana, Alabama, United States
3
Huntsville, Alabama, United States
4
Muscle Shoals, Alabama, United States